A CMH OBSTRUTIVA ESTÁ MAIS PERTO
DO QUE VOCÊ IMAGINA
A cardiomiopatia hipertrófica (CMH) é a doença cardíaca hereditária mais comum e, no entanto,
85% a 94% das pessoas provavelmente não são diagnosticadas. Vamos encontrá-los juntos.[1-4]
O que é CMH?
A CMH é uma doença cardiovascular crônica que progride ao longo do tempo.[5,6]
Saiba MaisAs Complicações da CMH
A CMH é mais prevalente do que você imagina e pode levar a um risco aumentado de comorbidades e mortalidade, além de impactar negativamente a vida diária dos pacientes.[1,5,7-9]
Explorar mais
Diagnosticando a CMH
Muitas vezes, a CMH é difícil de diagnosticar devido à sua apresentação variada e aos sintomas sobrepostos a outras
Tratamento da CMH
O monitoramento e a avaliação regulares dos pacientes são importantes, pois os medicamentos atuais são limitados principalmente ao controle dos
- Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65(12):1249-1254.
- Stanford Health Care. Hypertrophic cardiomyopathy. https://stanfordhealthcare.org/medical-conditions/blood-heartcirculation/hypertrophic-cardiomyopathy.html. Acessado em 14 de junho de 2021.
- Maron BJ, Rowin EJ, Maron MS. Global burden of hypertrophic cardiomyopathy. JACC: Heart Failure. 2018;6(5):376-378.
- Maron MS, Hellawell JL, Lucove JC, Farzaneh-Far R, Olivotto I. Occurrence of clinically diagnosed hypertrophic cardiomyopathy in the United States. Am J Cardiol. 2016;117(10):1651-1654.
- Ho CY, Day SM, Ashley EA, et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation. 2018;138(14):1387-1398.
- Olivotto I, Cecchi F, Poggesi C, Yacoub MH. Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging. Circ Heart Fail. 2012;5(4):535-546.
- Cox S, O’Donoghue AC, McKenna WJ, Steptoe A. Health related quality of life and psychological wellbeing in patients with hypertrophic cardiomyopathy. Heart. 1997;78(2):182-187.
- Huff CM, Turer AT, Wang A. Correlations between physician-perceived functional status, patient-perceived health status, and cardiopulmonary exercise results in hypertrophic cardiomyopathy. Qual Life Res. 2013;22(3):647-652.
- Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res. 2017;121(7):749-770.
- Canepa M, Fumagalli C, Tini G, et al; The SHaRe Investigators. Temporal trend of age at diagnosis in hypertrophic cardiomyopathy: an analysis of the International Sarcomeric Human Cardiomyopathy Registry. Circ Heart Fail. 2020;13(9):e0077230.
- Wexler R, Elton T, Pleister A, Feldman D. Cardiomyopathy: an overview. Am Fam Physician. 2009;79(9):778-784.
- Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733-2779.
- Ammirati E, Contri R, Coppini R, Cecchi F, Frigerio M, Olivotto I. Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. Eur J Heart Fail. 2016;18(9):1106-1118.